INSTITUT CLAUDIUS REGAUD
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-Ξ± Status in Patients With Metastatic Breast Cancer HER2 + and ERΞ± Neg Treated With Trastuzumab + Pertuzumab + Taxane.
- Conditions
- HER2-positive Breast Cancer
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 4
- Registration Number
- NCT03619044
- Locations
- π«π·
Centre Hospitalier Auch, Auch, France
π«π·Clinique Claude Bernard, Albi, France
π«π·Clinique Capio La Croix Du Sud, Quint-fonsegrives, France
Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Drug: Patients starting a treatment with Doxorubicin and Ifosfamide
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 59
- Registration Number
- NCT03514381
- Locations
- π«π·
Institut Bergonie, Bordeaux, France
π«π·Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France
π«π·Institut Regional Du Cancer de Montpellier (Icm), Montpellier, France
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
- Conditions
- Solid Cancers
- Interventions
- Other: Patients treated with immune checkpoint blockade
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 520
- Registration Number
- NCT03514368
- Locations
- π«π·
Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France
π«π·Chu Rangueil, Toulouse, France
π«π·Hopital Larrey, Toulouse, France
Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).
- Conditions
- Solid Tumor
- Interventions
- Other: Patients starting a treatment by ICI
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 150
- Registration Number
- NCT03447483
- Locations
- π«π·
Institut Regional Du Cancer de Montpellier (Icm), Montpellier, France
π«π·Institut Universitaire Du Cancer de Toulouse - Oncopole, Toulouse, France
π«π·CH ALBI, Albi, France
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
- Conditions
- Melanoma
- Interventions
- Combination Product: Combined treatment schemaCombination Product: Nivolumab + Ipilimumab
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 6
- Registration Number
- NCT03354962
- Locations
- π«π·
Chu Bordeaux, Bordeaux, France
π«π·Centre Oscar Lambret, Lille, France
π«π·CHU NICE, Nice, France
TNF in Melanoma Patients Treated With Immunotherapy
- Conditions
- Melanoma
- Interventions
- Other: Tumor biopsy specimens and blood samples
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 60
- Registration Number
- NCT03348891
- Locations
- π«π·
CHRU Claude HURIEZ, Lille, France
π«π·Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
π«π·CHU Montpellier Saint-Eloi, Montpellier, France
Optimization of the Patient Care Pathway in Immuno-oncology
- Conditions
- Melanoma
- Interventions
- Other: Dedicated and coordinated e-follow-up during the treatment periodOther: Standard follow-up during the treatment period
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 142
- Registration Number
- NCT03329755
- Locations
- π«π·
HΓ΄pital Saint AndrΓ©, CHU de Bordeaux, Bordeaux, France
π«π·Institut claudius regaud IUCT ONCOPOLE, Toulouse, France
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma
- Conditions
- Melanoma
- Interventions
- Combination Product: Nivolumab+Ipilimumab in combination with Anti TNF-Ξ± CertolizumabCombination Product: Nivolumab+Ipilimumab in combination with Anti TNF-Ξ± Infliximab
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 33
- Registration Number
- NCT03293784
- Locations
- π«π·
Institut Claudius Regaud IUCT-ONCOPOLE, Toulouse, France
Pilot Study Evaluating a Perioperative E-follow-up Protocol in Patients With Ambulatory Surgery for Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Other: Dedicated and coordinated e-follow-up.
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 40
- Registration Number
- NCT03289286
- Locations
- π«π·
Institut Claudius Regaud IUCT-ONCOPOLE, Toulouse, France
Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a Dedicated and Coordinated Follow-up Compared to Standard Follow-up.
- Conditions
- Metastatic Solid Tumor
- Interventions
- Other: Dedicated and coordinated follow-upOther: Standard follow-up
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 186
- Registration Number
- NCT03263416
- Locations
- π«π·
Clinique Des Cedres, Cornebarrieu, France
π«π·Clinique Claude Bernard, Albi, France
π«π·Institut Claudius Regaud, Toulouse, France